

May 8, 2025

CERTIFICATION

This certifies that the attached prescription data of **R06A - ANTIHISTAMINES SYSTEMIC in ABC - ORAL S ORD FILM-COATED TABS** covering the period:

MAT December 2024 (January 2024 – December 2024)

is a true extract of the IQVIA's Philippine Medical Data Index (PMDI) Report through IAM application. The above had been collated by IQVIA and, to the best of our knowledge, it reflects the prescription data of **R06A - ANTIHISTAMINES SYSTEMIC in ABC - ORAL S ORD FILM-COATED TABS** of PMDI and IAM published by IQVIA Solutions Philippines, Inc.

The Philippine Medical Data Index (PMDI) is a semestral qualitative study and reflects prescribing patterns as well as significant trends and developments in diagnosis and drug therapy. It should not be used as an accounting study. However, when using the report as a quantitative tool, the user is advised to take into account the standard error of the estimate. Furthermore, the user is advised to be careful in the use of regional data of the lower specialty groups as the sample base is small and since physicians are generally more individualistic in their practice.

GGG refers to a prescription wherein only the generic name was written by the physician. No brand nor company was specified.


Total Sample Size of 700 is within acceptable margin of error (MOE) of +/-5% at 95% confidence level, considering the Total IQVIA Universe List of 44,414.

As of date, latest IQVIA PMDI Audit is as of **MAT December 2024 (Jan 2024 – Dec 2024)**.

The next PMDI audit will be released no later than **June 15, 2025**. For the purpose of certifications issued based on PMDI, recently released certifications are valid until the latest PMDI report becomes available.

The information is provided on an "as is" basis and IQVIA does not warrant that the information contained herein shall meet the present or future needs or objectives of **Unilab, Inc.** who assumes sole responsibility for the use, selection, and suitability of the said information to its needs and objectives. IQVIA shall not be liable for any expressions of opinion, evaluations or forecasts contained in the said information. IQVIA does not accept or assume responsibility to any person or third party for any matter contained in or referred to in said information or for any reliance placed on the information contained in this letter.

Unilab, Inc. hereby undertake to indemnify IQVIA Solutions Philippines, Inc. for any and all loss, damage, cost (including reasonably legal fees) related to its use of the information.


MYLENE G. RODRIGUEZ
General Manager

ATC3 = R06A - ANTIHISTAMINES SYSTEMIC			
NFC3 = ABC - ORAL S ORD FILM-COATED TABS			
		MAT 2024/12	
Product	Molecule String	Rx- Prescriptions	Prescriptions Pct
LEVOCETIRIZINE - [GGG]	LEVOCETIRIZINE	237,368	39.2 %
ALNIX - [WMT]	CETIRIZINE	131,857	21.8 %
VIRLIX - [GSK]	CETIRIZINE	42,150	7.0 %
CETICIT - [AH/]	CETIRIZINE	37,548	6.2 %
PHILCET - [A4I]	LEVOCETIRIZINE	23,954	4.0 %
ALLERZET TAB - [UNA]	LEVOCETIRIZINE	23,386	3.9 %
XYZAL - [UCB]	LEVOCETIRIZINE	20,966	3.5 %
ZYRRIGIN - [UON]	CETIRIZINE	17,298	2.9 %
TRACEN - [CI+]	CETIRIZINE	13,420	2.2 %
SEDAZINE - [VIN]	HYDROXYZINE	9,819	1.6 %
AERIUS - [ORG]	DESLOTRATADINE	9,197	1.5 %
DESLOGEN - [IH4]	DESLOTRATADINE	7,642	1.3 %
EBASTINE - [GGG]	EBASTINE	5,420	0.9 %
ALEVA - [OEP]	EBASTINE	4,841	0.8 %
FEXOFENADINE - [GGG]	FEXOFENADINE	4,276	0.7 %
PURCET - [S+H]	LEVOCETIRIZINE	4,057	0.7 %
ALLERTEEN - [PED]	CETIRIZINE	3,466	0.6 %
TELFAS - [O/P]	FEXOFENADINE	2,990	0.5 %
ALLERGON - [AH/]	DESLOTRATADINE	1,953	0.3 %
PRIXLAE - [S2C]	CETIRIZINE	1,438	0.2 %
BENADRYL ONE - [JNT]	CETIRIZINE	1,007	0.2 %
ALLERMED - [NTA]	CETIRIZINE	742	0.1 %
LEVOCET-NATRAPHARM - [NTP]	LEVOCETIRIZINE	578	0.1 %
ZYRIZ - [YSS]	CETIRIZINE	447	0.1 %
CETRIWIN - [A4I]	CETIRIZINE	214	0.0 %
Grand Total		606,034	100.0 %

Prepared by: *Jonjon Buan*
Jonjon Buan

Checked by: *Pamela Irasusta*
Pamela Irasusta

USE OF IQVIA DATA
(IQVIA Data Disclosure Guidelines March 2007)

These Guidelines describe IQVIA SOLUTIONS PHILIPPINES, INC.'s Data Disclosure policies for the use and inclusion of IQVIA SOLUTIONS PHILIPPINES, INC.'s data and information in pharmaceutical company promotional activities, conferences, presentations, articles, other published material and educational interests. Any issues not addressed by these guidelines should be referred to Ms. Mylene G. Rodriguez, IQVIA SOLUTIONS PHILIPPINES, INC. (tel: 8683-6111). These guidelines shall not be interpreted to limit or impair IQVIA SOLUTIONS PHILIPPINES, INC.'s copyright and other intellectual and proprietary rights in its data and information services. IQVIA SOLUTIONS PHILIPPINES, INC. reserves the right to modify these Guidelines at any time.

1) Use of information in promotional materials and activity

The term promotion refers to any activity undertaken by a pharmaceutical company that promotes the prescription, supply, sale or administration of its medicines. It includes journal and direct mail, representatives' activities, supply of samples, inducements to prescribe, hospitality, sponsorship of promotional or scientific meetings participation in exhibitions, the use of films, web sites, recordings, etc.

1. A current signed data license agreement must be in place covering any IQVIA data which the clients wishes to include in any promotional material.
2. Clients wishing to include partial cuts of IQVIA data in any promotional material must first obtain prior written permission from IQVIA (See Procedure, outlined below).
3. Clients are responsible for ensuring that the proposed use of IQVIA data conforms to applicable laws and Codes of Practice in the countries in which they are to be used.
4. IQVIA will not be responsible for checking the validity of figures included in any promotional material, nor for ensuring that correct universes, market definitions, etc. have been used. It is the client's responsibility to ensure that data is not used in a misleading manner, and that appropriate time measures, values and market definitions have been used.
5. IQVIA is not responsible for any analyses or conclusions that have been independently arrived by the client based on the IQVIA data.
6. When incorporating IQVIA data into analyses for the purpose of a claim, client may not engage in the substantial republication or copying of the data in a manner that may impair IQVIA's ability to sell additional subscriptions to the data on a syndicated or other basis.
7. Where IQVIA data are to be used in promotional or other published material or to substantiate a claim, IQVIA must be identified as the source of the data together with the name of the IQVIA service from which the data are derived. For example: "Source: PMDI, IQVIA SOLUTIONS PHILIPPINES, INC., reprinted with permission". Products, market areas and time periods must also be accurately labeled so that the exact nature of the data is clear. Time periods, measures and clear market definition are all important to represent accurately.

Permitted Uses

Subject to above, references to a client's own products (and to own products within markets defined by the client) are permitted for publication in promotional material provided that they do not, either directly or indirectly, reveal individual information about other companies or their products.

A market including only the client's own product and one other should not be used, to avoid indirect identification of competitor information. Using a generic name instead of a brand name does not avoid the restriction on competitor data. However, mention of a generic name may be acceptable if it represents data from more than one other company (e.g., generic and branded sales of a product whose patent has expired).

As well as mentioning customers' own products, the client may be able to make comparisons (e.g., market share or average) of products within a relevant market (as long as this does not reveal information about an individual competitor or its products). This depends on the use being in accordance with local codes of practice, which is the company's responsibility to determine. For example, any averages or market shares must be calculated properly.

Competitor product details may be given in response to requests made for substantiation of claims, as may be required by local Codes of Practice, provided that such details are necessary to substantiate the claim in question, and the recipient of the data is warned that the information has been provided only for the purpose of substantiating the claim and may not be published or otherwise disclosed to any other party.

2) Use of IQVIA SOLUTIONS PHILIPPINES, INC's data and information in lawsuits or other legal matters

Clients or other third parties may not use IQVIA data and information in lawsuits or other legal matters without the prior written permission of IQVIA.

3) Use of IQVIA SOLUTIONS PHILIPPINES, INC's data and information by consultants and other third parties engaged by IQVIA clients.

A third party data use contract needs to be in place before IQVIA data or information licensed by a client is provided to a consultant or third party.

4) Use of IQVIA SOLUTIONS PHILIPPINES, INC's data and information in conference papers, presentations and articles.

Information can be used in conference papers, presentations and articles by obtaining prior written permission from IQVIA.

Please bear in mind the following:

- Data preferably should be high level, i.e. world/region/therapy area, top 10 etc.
- Product & molecule data showing brand names and that pertaining to company/product growth are particularly sensitive and should not be included.

IQVIA Solutions Philippines Inc.
Unit 6A, 6th Floor, 8 Rockwell Building, Hidalgo Drive
Rockwell Center, Makati City 1210 Philippines
iqvia.com

5) Use of IQVIA SOLUTIONS PHILIPPINES, INC's and information in financial disclosures, securities filings or shareholder solicitations

IQVIA data and information may not be used in financial disclosures, securities filings or solicitation without the prior written permission of IQVIA.

Procedure and Contact Details for Global Services

- Contact: Mylene G. Rodriguez, General Manager, Philippines
- Please include actual claim, where it will appear, and the copy of the supporting IQVIA data or information.
- For use by journalists, educational establishments and in publications that will be sold please refer to the above contact.

These guidelines and their administration will be reviewed and may be updated at any time at the discretion of IQVIA. Last updated 11/05/2018.

May 8, 2025

CERTIFICATION

This certifies that the attached sales data of **R06A - ANTIHISTAMINES SYSTEMIC in ABC - ORAL S ORD FILM-COATED TABS** in values covering the period:

MAT March 2025 (April 2024 – March 2025)

is a true extract of our Philippine Pharmaceutical Index (PPI) and Philippine Hospital Pharmaceutical Audit (PHPA) Reports through IAM application. The above had been collated by us and, to the best of our knowledge, it reflects the sales data of **R06A - ANTIHISTAMINES SYSTEMIC in ABC - ORAL S ORD FILM-COATED TABS** in the Philippine market. This data is similarly found in the **quarterly** reports of PPI and PPHA through IAM published by IQVIA Solutions Philippines, Inc.

The Philippine Pharmaceutical Index or PPI covers wholesale and retail drugstore plus other retail outlets such as: dispensing physicians, private clinics without beds, private offices/industrial entities and pharmaceutical traders. 93% of the total retail market are Distributors and Direct Manufacturers (DDM) or unprojected data while the remaining 7% is Panel data projected from 265 chain and independent drugstores.

The Philippine Hospital Pharmaceutical Audit or PPHA covers private and government hospitals plus clinics with beds, HMO's, Government Agencies and hospital traders. 85% of hospital market are Distributors and Direct Manufacturers (DDM) or unprojected data while the remaining 15% is panel data projected from 60 private hospitals and 39 government hospitals.

The information is provided on an "as is" basis and IQVIA does not warrant that the information contained herein shall meet the present or future needs or objectives of **Unilab Inc.** who assumes sole responsibility for the use, selection, and suitability of the said information to its needs and objectives. IQVIA shall not be liable for any expressions of opinion, evaluations or forecasts contained in the said information. IQVIA does not accept or assume responsibility to any person or third party for any matter contained in or referred to in said information or for any reliance placed on the information contained in this letter. **As of date, latest IQVIA Report is as of March 2025 audit period.**

Unilab Inc. undertake to indemnify IQVIA Solutions Philippines, Inc. for any and all loss, damage, cost (including reasonably legal fees) related to its use of the information.


MYLENE G. RODRIGUEZ
General Manager

ATC3 = R06A - ANTIHISTAMINES SYSTEMIC		
NFC3 = ABC - ORAL S ORD FILM-COATED TABS		
		MAT 2025/03
Product	Pack Molecule String	Values
ALNIX - [WMT]	CETIRIZINE	233,365,656
VIRLIX - [GSK]	CETIRIZINE	141,874,686
XYZAL - [UCB]	LEVOCETIRIZINE	62,282,205
ALLERZET TAB - [UNA]	LEVOCETIRIZINE	32,394,663
CETIRIZINE AMB ADI - [A4I]	CETIRIZINE	30,519,600
TEFAST - [O/P]	FEXOFENADINE	22,567,949
PHILCET - [A4I]	LEVOCETIRIZINE	20,434,613
BENADRYL ONE - [JNT]	CETIRIZINE	14,173,220
CETICIT - [AH/]	CETIRIZINE	12,064,986
ALEVA - [OEP]	EBASTINE	11,571,369
LEVOCETIRIZI RITEM - [RI/]	LEVOCETIRIZINE	11,503,908
CETIZINE - [HSV]	CETIRIZINE	7,868,192
LORAGIC - [SDZ]	LORATADINE	6,250,128
CTZ - [D&B]	CETIRIZINE	6,189,954
AERIUS - [ORG]	DES Loratadine	5,808,681
CETRINOVA - [MNV]	CETIRIZINE	3,263,270
LEVOCETIRIZI TPI - [A4I]	LEVOCETIRIZINE	2,688,784
EOFEN-120 - [EO.]	FEXOFENADINE	2,649,420
CETIRIZINE RITEM - [RI/]	CETIRIZINE	2,571,700
QUALCET - [A4I]	CETIRIZINE	1,949,548
IRIZINE-10 - [PGP]	CETIRIZINE	1,847,985
CETIRINE - [JRL]	CETIRIZINE	1,607,992
ZYRIZ - [YSS]	CETIRIZINE	1,272,326
HISTALEV - [SUS]	LEVOCETIRIZINE	819,676
CETIRIZINE WPC HSP - [HSV]	CETIRIZINE	680,296
COALBI - [JZM]	LEVOCETIRIZINE	553,227
GOTIRIZINE - [MNV]	CETIRIZINE	485,625
ALLERMED - [NTA]	CETIRIZINE	267,143
SEDAZINE - [VIN]	HYDROXYZINE	250,292
TRACEN - [CI+]	CETIRIZINE	218,242
ZYRRIGIN - [UON]	CETIRIZINE	217,971
LEVIZINE - [HXA]	LEVOCETIRIZINE	200,700
PURCET - [S+H]	LEVOCETIRIZINE	110,894
CETOZ-L - [RAQ]	LEVOCETIRIZINE	91,427
LOCETIN - [PKC]	LEVOCETIRIZINE	6,058
EOCET - [EO.]	CETIRIZINE	4,352
Grand Total		640,626,738

Prepared by: *Jonjon Buan*
Jonjon Buan

Checked by: *Pamela Irasusta*
Pamela Irasusta

USE OF IQVIA DATA
(IQVIA Data Disclosure Guidelines March 2007)

These Guidelines describe IQVIA SOLUTIONS PHILIPPINES, INC.'s Data Disclosure policies for the use and inclusion of IQVIA SOLUTIONS PHILIPPINES, INC.'s data and information in pharmaceutical company promotional activities, conferences, presentations, articles, other published material and educational interests. Any issues not addressed by these guidelines should be referred to Ms. Mylene G. Rodriguez, IQVIA SOLUTIONS PHILIPPINES, INC. (tel: 683-6111). These guidelines shall not be interpreted to limit or impair IQVIA SOLUTIONS PHILIPPINES, INC.'s copyright and other intellectual and proprietary rights in its data and information services. IQVIA SOLUTIONS PHILIPPINES, INC. reserves the right to modify these Guidelines at any time.

1) Use of information in promotional materials and activity

The term promotion refers to any activity undertaken by a pharmaceutical company that promotes the prescription, supply, sale or administration of its medicines. It includes journal and direct mail, representatives' activities, supply of samples, inducements to prescribe, hospitality, sponsorship of promotional or scientific meetings participation in exhibitions, the use of films, web sites, recordings, etc.

1. A current signed data license agreement must be in place covering any IQVIA data which the clients wishes to include in any promotional material.
2. Clients wishing to include partial cuts of IQVIA data in any promotional material must first obtain prior written permission from IQVIA (See Procedure, outlined below).
3. Clients are responsible for ensuring that the proposed use of IQVIA data conforms to applicable laws and Codes of Practice in the countries in which they are to be used.
4. IQVIA will not be responsible for checking the validity of figures included in any promotional material, nor for ensuring that correct universes, market definitions, etc. have been used. It is the client's responsibility to ensure that data is not used in a misleading manner, and that appropriate time measures, values and market definitions have been used.
5. IQVIA is not responsible for any analyses or conclusions that have been independently arrived by the client based on the IQVIA data.
6. When incorporating IQVIA data into analyses for the purpose of a claim, client may not engage in the substantial republication or copying of the data in a manner that may impair IQVIA's ability to sell additional subscriptions to the data on a syndicated or other basis.
7. Where IQVIA data are to be used in promotional or other published material or to substantiate a claim, IQVIA must be identified as the source of the data together with the name of the IQVIA service from which the data are derived. For example: "Source: PMDI, IQVIA SOLUTIONS PHILIPPINES, INC., reprinted with permission". Products, market areas and time periods must also be accurately labeled so that the exact nature of the data is clear. Time periods, measures and clear market definition are all important to represent accurately.

Permitted Uses

Subject to above, references to a client's own products (and to own products within markets defined by the client) are permitted for publication in promotional material provided that they do not, either directly or indirectly, reveal individual information about other companies or their products.

A market including only the client's own product and one other should not be used, to avoid indirect identification of competitor information. Using a generic name instead of a brand name does not avoid the restriction on competitor data. However, mention of a generic name may be acceptable if it represents data from more than one other company (e.g., generic and branded sales of a product whose patent has expired).

As well as mentioning customers' own products, the client may be able to make comparisons (e.g., market share or average) of products within a relevant market (as long as this does not reveal information about an individual competitor or its products). This depends on the use being in accordance with local codes of practice, which is the company's responsibility to determine. For example, any averages or market shares must be calculated properly.

Competitor product details may be given in response to requests made for substantiation of claims, as may be required by local Codes of Practice, provided that such details are necessary to substantiate the claim in question, and the recipient of the data is warned that the information has been provided only for the purpose of substantiating the claim and may not be published or otherwise disclosed to any other party.

2) Use of IQVIA SOLUTIONS PHILIPPINES, INC's data and information in lawsuits or other legal matters

Clients or other third parties may not use IQVIA data and information in lawsuits or other legal matters without the prior written permission of IQVIA.

3) Use of IQVIA SOLUTIONS PHILIPPINES, INC's data and information by consultants and other third parties engaged by IQVIA clients.

A third party data use contract needs to be in place before IQVIA data or information licensed by a client is provided to a consultant or third party.

4) Use of IQVIA SOLUTIONS PHILIPPINES, INC's data and information in conference papers, presentations and articles.

Information can be used in conference papers, presentations and articles by obtaining prior written permission from IQVIA.

Please bear in mind the following:

- Data preferably should be high level, i.e. world/region/therapy area, top 10 etc.
- Product & molecule data showing brand names and that pertaining to company/product growth are particularly sensitive and should not be included.

IQVIA Solutions Philippines Inc.
Unit 6A, 6th Floor, 8 Rockwell Building, Hidalgo Drive
Rockwell Center, Makati City 1210 Philippines
iqvia.com

5) Use of IQVIA SOLUTIONS PHILIPPINES, INC's and information in financial disclosures, securities filings or shareholder solicitations

IQVIA data and information may not be used in financial disclosures, securities filings or solicitation without the prior written permission of IQVIA.

Procedure and Contact Details for Global Services

- Contact: Mylene G. Rodriguez, General Manager, Philippines
- Please include actual claim, where it will appear, and the copy of the supporting IQVIA data or information.
- For use by journalists, educational establishments and in publications that will be sold please refer to the above contact.

These guidelines and their administration will be reviewed and may be updated at any time at the discretion of IQVIA. Last updated 11/05/2018.